Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
Emmanuel Kwateng Drokow,1 Hafiz Abdul Waqas Ahmed,1 Cecilia Amponsem-Boateng,2 Gloria Selorm Akpabla,3 Juanjuan Song,1 Mingyue Shi,1 Kai Sun11Department of Hematology, Zhengzhou University People‘s Hospital & Henan Provincial People‘s Hospital Henan, Zhengzhou, People&...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-05-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/survival-outcomes-and-efficacy-of-autologous-cd19-chimeric-antigen-rec-peer-reviewed-article-TCRM |
| _version_ | 1818421583745646592 |
|---|---|
| author | Drokow EK Ahmed HAW Amponsem-Boateng C Akpabla GS Song J Shi M Sun K |
| author_facet | Drokow EK Ahmed HAW Amponsem-Boateng C Akpabla GS Song J Shi M Sun K |
| author_sort | Drokow EK |
| collection | DOAJ |
| description | Emmanuel Kwateng Drokow,1 Hafiz Abdul Waqas Ahmed,1 Cecilia Amponsem-Boateng,2 Gloria Selorm Akpabla,3 Juanjuan Song,1 Mingyue Shi,1 Kai Sun11Department of Hematology, Zhengzhou University People‘s Hospital & Henan Provincial People‘s Hospital Henan, Zhengzhou, People’s Republic of China; 2Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, People’s Republic of China; 3Department of Internal Medicine, Tianjin Medical University, Tianjin, People’s Republic of ChinaPurpose: Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades. It becomes the preferred treatment choice after patients have failed conventional chemotherapy.Methods: We conducted a meta-analysis in 320 patients from 14 studies to estimate the survival outcome, response rate and toxicity of autologous CD19 CAR-T cell therapy and predict other factors associated with a better prognosis.Results: The overall response rate was 71.88% (95% CI: 61.34–80.46%, p<0.01) and CRS toxicity was 60.15% (95% CI: 42.87–75.22%, p<0.01). Patients who received lymphodepletion was associated with a better response rate (77%, 95%CI: 67–83%; p-value =0.001) in comparison to the other patients who did not (66%, 95%CI: 41–83%).Conclusion: Lymphodepletion regimen may play a crucial role in predicting the prognosis of patients with hematological malignancies. Lymphodepletion patients had better progression-free survival than those who did not.Keywords: autologous, CD19, CAR-T, hematological malignancies, response rate |
| first_indexed | 2024-12-14T13:12:40Z |
| format | Article |
| id | doaj.art-0a5c552a7f454c9fb414c61d736147d8 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-14T13:12:40Z |
| publishDate | 2019-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-0a5c552a7f454c9fb414c61d736147d82022-12-21T23:00:08ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2019-05-01Volume 1563764645623Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysisDrokow EKAhmed HAWAmponsem-Boateng CAkpabla GSSong JShi MSun KEmmanuel Kwateng Drokow,1 Hafiz Abdul Waqas Ahmed,1 Cecilia Amponsem-Boateng,2 Gloria Selorm Akpabla,3 Juanjuan Song,1 Mingyue Shi,1 Kai Sun11Department of Hematology, Zhengzhou University People‘s Hospital & Henan Provincial People‘s Hospital Henan, Zhengzhou, People’s Republic of China; 2Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, People’s Republic of China; 3Department of Internal Medicine, Tianjin Medical University, Tianjin, People’s Republic of ChinaPurpose: Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades. It becomes the preferred treatment choice after patients have failed conventional chemotherapy.Methods: We conducted a meta-analysis in 320 patients from 14 studies to estimate the survival outcome, response rate and toxicity of autologous CD19 CAR-T cell therapy and predict other factors associated with a better prognosis.Results: The overall response rate was 71.88% (95% CI: 61.34–80.46%, p<0.01) and CRS toxicity was 60.15% (95% CI: 42.87–75.22%, p<0.01). Patients who received lymphodepletion was associated with a better response rate (77%, 95%CI: 67–83%; p-value =0.001) in comparison to the other patients who did not (66%, 95%CI: 41–83%).Conclusion: Lymphodepletion regimen may play a crucial role in predicting the prognosis of patients with hematological malignancies. Lymphodepletion patients had better progression-free survival than those who did not.Keywords: autologous, CD19, CAR-T, hematological malignancies, response ratehttps://www.dovepress.com/survival-outcomes-and-efficacy-of-autologous-cd19-chimeric-antigen-rec-peer-reviewed-article-TCRMAutologousCD19CAR-Thaematological malignanciesResponse rate |
| spellingShingle | Drokow EK Ahmed HAW Amponsem-Boateng C Akpabla GS Song J Shi M Sun K Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis Therapeutics and Clinical Risk Management Autologous CD19 CAR-T haematological malignancies Response rate |
| title | Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis |
| title_full | Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis |
| title_fullStr | Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis |
| title_full_unstemmed | Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis |
| title_short | Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis |
| title_sort | survival outcomes and efficacy of autologous cd19 chimeric antigen receptor t cell therapy in the patient with diagnosed hematological malignancies a systematic review and meta analysis |
| topic | Autologous CD19 CAR-T haematological malignancies Response rate |
| url | https://www.dovepress.com/survival-outcomes-and-efficacy-of-autologous-cd19-chimeric-antigen-rec-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT drokowek survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT ahmedhaw survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT amponsemboatengc survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT akpablags survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT songj survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT shim survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT sunk survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis |